Prognostic Biomarkers of Head and Neck Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1071
Special Issue Editor
2. Division of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, CA 90095, USA
Interests: head and neck cancer; prognosis prediction; cancer biomarkers
Special Issue Information
Dear Colleagues,
Head and neck cancer (HNC) is a common form of malignancy that predominantly affects regions including the nasal and oral cavities, oropharynx, pharynx, hypopharynx, larynx, thyroid, and salivary glands. Established risk factors such as alcohol and tobacco use, alongside human papillomavirus infections, play crucial roles in its pathogenesis and prognosis. Despite remarkable advances in understanding the disease's etiology and management due to the deployment of cutting-edge techniques, the prognosis for HNC has only seen a modest enhancement.
Prognostic biomarkers are biological indicators linked with the disease's long-term outcomes or progression. They could comprise genes, mRNAs, non-coding RNAs, proteins, and metabolites. The recognition of robust and precise prognostic biomarkers for HNC patients is of paramount importance. They can help identify patient subpopulations likely to experience varied outcomes or who may benefit from particular treatments. Implementing biomarkers may also curtail the incidence of negative biopsies and misdiagnoses, reducing the necessity for recurrent biopsies and imaging procedures. Furthermore, biomarkers predicting the response or resistance to HNC therapies can significantly enhance patient management. Nevertheless, the incorporation of biomarkers into clinical practice has been limited, thus necessitating the development and validation of novel prognostic biomarkers.
In this Special Issue, we solicit submissions that explore innovative biomarkers in various clinical settings to advance the management of HNC. These biomarkers could enable early therapeutic interventions, proactive monitoring for metastasis detection, and improved HNC patient management. We also welcome studies employing experimental analysis to elucidate the molecular mechanisms underpinning these chosen biomarkers. We eagerly anticipate your valuable contributions.
Dr. Li Cui
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- head and neck cancer
- prognosis prediction
- cancer biomarkers
- tumor progression
- patient management
- molecular mechanism
